496
+4.20%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kringle Pharma
Its shares trade on Tokyo Stock Exchange under the ticker 4884.T. It has been listed since 28 December 2020. In the fiscal year to 30 September 2025, it reported revenue of ¥72.2m and a net loss of ¥916.3m. At that date it held total assets of ¥2.08bn and shareholders' equity of ¥1.31bn.
Kringle Pharma, Inc. engages in the research and development of treatments for regenerative medicine and cancer therapy. The company is headquartered in Ibaraki-Shi, Osaka-Fu. The company went IPO on 2020-12-28. The firm is involved in the research and development of therapeutic agents for intractable diseases using hepatocyte growth factor (HGF) protein. HGF has versatile bioactivity that is responsible for tissue or organ regeneration and protection such as cell proliferation promotion, cell motility promotion, anti-apoptosis, morphogenesis induction, and angiogenesis. HGF has a therapeutic effect on chronic fibrotic diseases such as liver cirrhosis, chronic renal failure, pulmonary fibrosis and cardiomyopathy. HGFs target diseases are Atrophic lateral sclerosis (ALS), Acute renal impairment, Vocal scar and others. The firm is involved in the general new drug development processes such as basic research, non-clinical trials and manufacturing, clinical trials, approval application and authorization, marketing and expansion of indications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Dec 2020
- Employees
- 12
- Website
- kringle-pharma.com ↗
Leadership
Pay as last reported
- Dr. Kiichi AdachiPresident, Chief Executive Officer, Representative Director, since 2004
- Mr. Koichi MurakamiDirector of Business Administration, Director, since 2021
- Mr. Daishin HayataDirector of Pharmaceutical Development, Director, since 2022
- Mr. Yoshiyuki ChinoDirector
- Dr. Akihiro TomoyasuDirector
- Dr. Masato FukuiIndependent Director
- Mr. Koichiro YoshinoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kringle Pharma focuses on regenerative medicine and cancer therapy treatments.
- The firm utilizes hepatocyte growth factor for therapeutic agent development.
- Research covers basic studies, trials, and manufacturing processes.
Weaknesses
- The company has only twelve employees in the biotechnology sector.
- Operations are limited to the Japanese domestic market.
- Listing occurred recently on twenty-eighth December two thousand twenty.
Opportunities
- HGF shows potential for treating chronic fibrotic diseases like liver cirrhosis.
- Therapeutic effects extend to acute renal impairment and vocal scars.
- Expansion into marketing and authorization of new indications is possible.
Threats
- Development of intractable diseases faces complex regulatory approval applications.
- Clinical trials require significant resources and time to complete.
- Market competition in biotechnology remains intense and challenging.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.